These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 39044835)

  • 1. Advances in second hematopoietic stem cell transplantation.
    Yan S; Zhu X; Xiao Y
    Front Immunol; 2024; 15():1428101. PubMed ID: 39044835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors of second hematopoietic allogeneic stem cell transplantation among hematological malignancy patients relapsed after first hematopoietic stem cell transplantation: A single center study.
    Lu Y; Zhang JP; Zhao YL; Xiong M; Sun RJ; Cao XY; Wei ZJ; Zhou JR; Liu DY; Yang JF; Zhang X; Lu DP; Lu P
    Front Immunol; 2022; 13():1066748. PubMed ID: 36685540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy and safety of secondary allogeneic hematopoietic stem cell transplantation in 70 patients with recurrent hematologic malignancies after transplantation].
    Han TT; Liu Y; Chen Y; Zhang YY; Fu HX; Yan CH; Mo XD; Wang FR; Wang JZ; Han W; Chen YY; Chen H; Sun YQ; Cheng YF; Wang Y; Zhang XH; Huang XJ; Xu LP
    Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):458-464. PubMed ID: 37550200
    [No Abstract]   [Full Text] [Related]  

  • 4. Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia/myelodysplastic syndromes after a first transplantation.
    Yerushalmi Y; Shem-Tov N; Danylesko I; Canaani J; Avigdor A; Yerushalmi R; Nagler A; Shimoni A
    Haematologica; 2023 Jul; 108(7):1782-1792. PubMed ID: 36475520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome of second allogeneic hematopoietic stem cell transplantation (HSCT2) for primary graft failure in patients with acute leukemia in remission: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Nagler A; Labopin M; Swoboda R; Kulagin A; Velardi A; Sanz J; Labussière-Wallet H; Potter V; Kuball J; Sica S; Parovichnikova E; Bethge W; Maillard N; Platzbecker U; Stölzel F; Ciceri F; Mohty M
    Bone Marrow Transplant; 2023 Sep; 58(9):1008-1016. PubMed ID: 37253804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change.
    Christopeit M; Kuss O; Finke J; Bacher U; Beelen DW; Bornhäuser M; Schwerdtfeger R; Bethge WA; Basara N; Gramatzki M; Tischer J; Kolb HJ; Uharek L; Meyer RG; Bunjes D; Scheid C; Martin H; Niederwieser D; Kröger N; Bertz H; Schrezenmeier H; Schmid C
    J Clin Oncol; 2013 Sep; 31(26):3259-71. PubMed ID: 23918951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies.
    Naik S; Martinez C; Leung K; Sasa G; Nguyen NY; Wu MF; Gottschalk S; Brenner M; Heslop H; Krance R
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1266-72. PubMed ID: 25765555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second allogeneic hematopoietic stem cell transplantation in patients with acute leukemia relapsed after allogeneic hematopoietic stem cell transplantation.
    Choi Y; Choi EJ; Lee JH; Lee KH; Jo JC; Park HS; Lee YJ; Seol M; Lee YS; Kang YA; Jeon M; Lee JH
    Clin Transplant; 2021 Mar; 35(3):e14199. PubMed ID: 33349948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second allogeneic hematopoietic stem cell transplantation for leukemia relapse after first allogeneic transplantation: outcome of 16 patients in a single institution.
    Tomonari A; Iseki T; Ooi J; Nagayama H; Sato H; Takahashi T; Ito K; Nagamura F; Uchimaru K; Takahashi S; Shirafuji N; Tojo A; Tani K; Asano S
    Int J Hematol; 2002 Apr; 75(3):318-23. PubMed ID: 11999364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage haploidentical or cord-blood allogeneic stem cell transplantation after a prior alternative allograft in hematologic malignancies: A retrospective study from the SFGM-TC.
    Cavalieri D; Rubio MT; Corriger A; Pereira B; Cabrespine A; Robin M; Labussière-Wallet H; Calleja A; Forcade E; Chevallier P; Guillerm G; Berceanu A; Bulabois CE; Maillard N; Nguyen S; Raus N; Schoemans H; Bay JO; Ravinet A
    Eur J Haematol; 2023 Jan; 110(1):40-49. PubMed ID: 36151965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second unmanipulated allogeneic transplantation could be used as a salvage option for patients with relapsed acute leukemia post-chemotherapy plus modified donor lymphocyte infusion.
    Han T; Sun Y; Liu Y; Yan C; Wang Y; Xu L; Liu K; Huang X; Zhang X
    Front Med; 2021 Oct; 15(5):728-739. PubMed ID: 34279770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The importance of graft cell composition in outcome after allogeneic stem cell transplantation in patients with malignant disease.
    Svenberg P; Wang T; Uhlin M; Watz E; Remberger M; Ringden O; Mattsson J; Uzunel M
    Clin Transplant; 2019 Jun; 33(6):e13537. PubMed ID: 30873642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Second allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and donor changes in relapsed hematological malignancies after the first allogeneic transplant].
    Zhao YQ; Song YZ; Li ZH; Yang F; Xu T; Li FF; Yang DF; Wu T
    Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):465-471. PubMed ID: 37550201
    [No Abstract]   [Full Text] [Related]  

  • 16. [Analysis of risk factors for relapse of 82 patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation].
    Yu ZP; Ding JH; Chen BA; Wu F; Gao C; Sun YY; Chen J; Zhao G; Wang J; Li YF; Ding BH; Qian J
    Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):283-6. PubMed ID: 21575500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of third allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute leukemia after a second transplantation.
    Kobayashi S; Kanda Y; Konuma T; Inamoto Y; Matsumoto K; Uchida N; Ikegame K; Miyamoto T; Doki N; Nakamae H; Katayama Y; Takahashi S; Shiratori S; Saito S; Kawakita T; Kanda J; Fukuda T; Atsuta Y; Kimura F
    Bone Marrow Transplant; 2022 Jan; 57(1):43-50. PubMed ID: 34625663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis.
    Edahiro T; Kawase T; Nagoshi H; Fujino K; Toishigawa K; Miyama T; Mino T; Yoshida T; Morioka T; Hirata Y; Noma M; Fujii T; Nishizawa M; Fukushima N; Ichinohe T
    Hematology; 2021 Dec; 26(1):186-198. PubMed ID: 33594942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy.
    Levine JE; Uberti JP; Ayash L; Reynolds C; Ferrara JL; Silver SM; Braun T; Yanik G; Hutchinson R; Ratanatharathorn V
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):189-97. PubMed ID: 12652470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate.
    Perez-Simón JA; Martino R; Parody R; Cabrero M; Lopez-Corral L; Valcarcel D; Martinez C; Solano C; Vazquez L; Márquez-Malaver FJ; Sierra J; Caballero D
    Haematologica; 2013 Apr; 98(4):526-32. PubMed ID: 23065527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.